Market Place
Sourcing Support
Agios Presents New Data on Mitapivat & Tebapivat at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Agios Reports Business Highlights and Q3 2024 Financial Results
31 Oct 2024 //
GLOBENEWSWIRE
Agios Completes Enrollment of Phase 3 RISE UP Study
23 Oct 2024 //
GLOBENEWSWIRE
Agios To Webcast Conference Call Q3 2024 Financial Results On Oct 31
17 Oct 2024 //
GLOBENEWSWIRE
Agios To Present At Cantor Global Healthcare Conference
05 Sep 2024 //
GLOBENEWSWIRE
Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval
06 Aug 2024 //
GLOBENEWSWIRE
Agios Announces Phase 3 ACTIVATE-KidsT Study Results
01 Aug 2024 //
GLOBENEWSWIRE
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Agios` Pyrukynd Misses Mark In First Pediatric Study
01 Aug 2024 //
FIERCE PHARMA
Agios Schedules Q2 2024 Financial Results Webcast For August 1
18 Jul 2024 //
GLOBENEWSWIRE
Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA
15 Jun 2024 //
GLOBENEWSWIRE
Update: Agios To Present At Goldman Healthcare Conf June 10 8:40am ET
06 Jun 2024 //
GLOBENEWSWIRE
Agios` Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias
03 Jun 2024 //
GLOBENEWSWIRE
Agios Pharmaceuticals` blood disorder drug succeeds in late-stage study
03 Jun 2024 //
REUTERS
Agios At Goldman Sachs Healthcare Conference On June 10
30 May 2024 //
GLOBENEWSWIRE
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
28 May 2024 //
BIOPHARMADIVE
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
28 May 2024 //
GLOBENEWSWIRE
Agios To Present Rare Blood Disorder Data At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Agios To Present At BofA Healthcare Conference On May 16
06 May 2024 //
GLOBENEWSWIRE
Agios To Present At RBC Healthcare Conference On May 14
03 May 2024 //
GLOBENEWSWIRE
Agios To Webcast Q1 2024 Financial Results On May 2
18 Apr 2024 //
GLOBENEWSWIRE
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
09 Apr 2024 //
GLOBENEWSWIRE
Agios to Present at the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
Agios to Present at TD Cowen 44th Annual Health Care Conference on March 4, 2024
22 Feb 2024 //
GLOBENEWSWIRE
Agios Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Agios to Webcast Conference of Fourth Quarter & Year End 2023 Financial Results
02 Feb 2024 //
GLOBENEWSWIRE
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
08 Jan 2024 //
GLOBENEWSWIRE
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint
03 Jan 2024 //
GLOBENEWSWIRE
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Agios Presents Results from Phase 2 of the RISE UP Study in Sickle Cell Disease
09 Dec 2023 //
GLOBENEWSWIRE
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946
20 Nov 2023 //
GLOBENEWSWIRE
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Agios to Present Broad Set of Translational Data in Rare Blood Disorders
02 Nov 2023 //
GLOBENEWSWIRE
Agios to Webcast Conference of Third Quarter 2023 Financial Results on Nov. 2
19 Oct 2023 //
GLOBENEWSWIRE
Agios to Present at the Morgan Stanley Global Healthcare Conference Sep 12, 2023
29 Aug 2023 //
GLOBENEWSWIRE
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA
03 Aug 2023 //
GLOBENEWSWIRE
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Agios pays $17.5M for Alnylam`s siRNA blood disease program
03 Aug 2023 //
FIERCE BIOTECH
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results
13 Jul 2023 //
GLOBENEWSWIRE
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study
26 Jun 2023 //
GLOBENEWSWIRE
Looking to expand Pyrukynd label, Agios treks toward PIII in sickle cell disease
26 Jun 2023 //
ENDPTS
Agios to Present at Goldman Sachs Global Healthcare Conference on June 15, 2023
05 Jun 2023 //
GLOBENEWSWIRE
Agios Appoints Catherine Owen to Board of Directors
25 May 2023 //
GLOBENEWSWIRE
Agios to Present Translational Data at European Hematology Association Congress
11 May 2023 //
GLOBENEWSWIRE
Agios Reports Business Highlights and First Quarter 2023 Financial Results
04 May 2023 //
GLOBENEWSWIRE
Agios to Present at the RBC Capital Markets Global Healthcare Conference
25 Apr 2023 //
GLOBENEWSWIRE
Agios Appoints Jeffrey Capello to Board of Directors
19 Apr 2023 //
GLOBENEWSWIRE
Agios to Webcast Conference of Q1 2023 Financial Results on May 4, 2023
13 Apr 2023 //
GLOBENEWSWIRE
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
03 Apr 2023 //
GLOBENEWSWIRE
Agios to Participate in March Investor Conferences
02 Mar 2023 //
GLOBENEWSWIRE
Agios Launches “Red Cell Revolution†in Recognition of Rare Disease Day
28 Feb 2023 //
GLOBENEWSWIRE
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Agios to Webcast Conference of Q4 and Year End 2022 Financial Results
02 Feb 2023 //
GLOBENEWSWIRE
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company`s Vision
08 Jan 2023 //
GLOBENEWSWIRE
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jan 2023 //
GLOBENEWSWIRE
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday
21 Dec 2022 //
GLOBENEWSWIRE
Agios Presents PYRUKYND Data Demonstrating Sustained Clinical Benefit in Adults
11 Dec 2022 //
GLOBENEWSWIRE
Agios Presents Updated PYRUKYND® Data Highlighting Long-term Safety Profile
10 Dec 2022 //
GLOBENEWSWIRE
Agios Appoints Tsveta Milanova as Chief Commercial Officer
06 Dec 2022 //
GLOBENEWSWIRE
Agios` Pyrukynd Receives Approval in Europe
05 Dec 2022 //
EMA
